In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia

Редактирование основания PCSK9 in vivo с использованием VERVE-102 при гиперхолестеринемии
David Ernest Newby, Handrean Soran, Sekar Kathiresan, Riyaz S. Patel, Steve Eric Humphries, Daniel Gaudet, Riyaz S. Patel, Amit V. Khera, Rick Falzone, Jörg Täubel, Leslie E. Stolz, Scott B. Vafai, Liam R. Brunham, Xinyan Zhang, Alexander Abitbol, Jane Kerr, Stephen J Nicholls, Thomas Ashdown, Sadaf Diamondali, Jaimini Cegla, Handrean Soran, Bilal Bashir, D Gaudet, Alex Lauzière, Liam R. Brunham, S Nicholls, Russell S. Scott, Jane Kerr, Jean-Claude Tardif, Catherine Lunken, Steve E. Humphries, Verena Karsten, Patrick D. Tyler, Nidal Huniti, Patrick A. Flight, Chelsey L. Jensen, Joseph C. Biedenkapp, Troy Lister, Amit V. Khera, Sekar Kathiresan, Jean‐Claude Tardif, Thomas Ashdown, Bilal Bashir, Chelsey J. Jensen
2026-05-25

GalNAc-conjugate deliveryLDL cholesterolPCSK9VERVE-102in vivo base editing
BACKGROUND: in the liver. METHODS: -acetylgalactosamine. The objectives were to assess safety and changes in blood PCSK9 protein and LDL cholesterol levels. RESULTS: A total of 35 participants across the six dose cohorts received VERVE-102 and had at least 28 days of follow-up. No dose-limiting toxic effects occurred. Mild-to-moderate infusion-related reactions and transient elevations in alanine aminotransferase levels were observed. Aspiration pneumonitis occurred in a participant with gastroesophageal reflux disease. Dose-dependent mean reductions in the PCSK9 level ranged from 51% at the 0.3-mg-per-kilogram dose to 88% at the 1.0-mg-per-kilogram dose. Corresponding reductions in the LDL cholesterol level ranged from 9% at the 0.3-mg-per-kilogram dose to 62% at the 1.0-mg-per-kilogram dose, with an absolute reduction of 78 mg per deciliter at the highest dose. Reductions appeared to be durable throughout follow-up, which was at least 1 year in 15 participants. CONCLUSIONS: One dose of VERVE-102 led to dose-dependent, substantial, and sustained reductions in PCSK9 and LDL cholesterol levels. (Funded by Verve Therapeutics; ClinicalTrials.gov number, NCT06164730.).
1
Corresponding LDL cholesterol reductions were dose-dependent, ranging from 9% at 0.3 mg/kg to 62% at 1.0 mg/kg, with an absolute 78 mg/dL reduction at the highest dose.
2
No dose-limiting toxic effects observed; adverse events included mild-to-moderate infusion-related reactions, transient alanine aminotransferase elevations, and one case of aspiration pneumonitis in a participant with gastroesophageal reflux disease.
3
Reductions in PCSK9 and LDL cholesterol appeared durable, maintained throughout follow-up of at least one year in 15 participants.
4
Single intravenous dose of VERVE-102 produced dose-dependent reductions in blood PCSK9 protein levels, from 51% at 0.3 mg/kg to 88% at 1.0 mg/kg.
5
Study enrolled 35 participants across six dose cohorts and assessed safety and biomarker changes after in vivo liver-targeted base editing using VERVE-102.

VERVE-102 in vivo base-editing therapeutic administered to human participants with hypercholesterolemia

Safety and dose-dependent effects of a single VERVE-102 dose on blood PCSK9 protein levels and LDL cholesterol reductions (efficacy and durability)

Publication Details
Publication Date
2026-05-25
Journal
Publisher
ISSN
Cited by
40
Access Type
Author Information
Authors
David Ernest Newby
Handrean Soran
Sekar Kathiresan
Riyaz S. Patel
Steve Eric Humphries
Daniel Gaudet
Riyaz S. Patel
Amit V. Khera
Rick Falzone
Jörg Täubel
Leslie E. Stolz
Scott B. Vafai
Liam R. Brunham
Xinyan Zhang
Alexander Abitbol
Jane Kerr
Stephen J Nicholls
Thomas Ashdown
Sadaf Diamondali
Jaimini Cegla
Handrean Soran
Bilal Bashir
D Gaudet
Alex Lauzière
Liam R. Brunham
S Nicholls
Russell S. Scott
Jane Kerr
Jean-Claude Tardif
Catherine Lunken
Steve E. Humphries
Verena Karsten
Patrick D. Tyler
Nidal Huniti
Patrick A. Flight
Chelsey L. Jensen
Joseph C. Biedenkapp
Troy Lister
Amit V. Khera
Sekar Kathiresan
Jean‐Claude Tardif
Thomas Ashdown
Bilal Bashir
Chelsey J. Jensen
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%